CJC-1295 (No DAC) / Ipamorelin

CJC-1295 (No DAC) / Ipamorelin is a high-purity, research-grade peptide combination widely utilized in laboratory and preclinical research focused on growth hormone signaling, receptor synergy, and endocrine pathway modulation. This formulation pairs a short-acting growth hormone–releasing hormone (GHRH) analog with a selective ghrelin receptor agonist, enabling researchers to study complementary peptide-mediated mechanisms within controlled research models.

The combined profile of CJC-1295 (No DAC) and Ipamorelin supports detailed investigation into coordinated growth hormone release dynamics, receptor interactions, and peptide synergy in endocrine research settings.

Key Features:

• Research-grade purity with strict quality control and batch consistency

• Multi-peptide formulation designed for synergy-based research models

• Optimized for in vitro and preclinical research applications

• Supports studies in growth hormone signaling and receptor interaction pathways

• Supplied with detailed handling, storage, and reconstitution instructions to maintain peptide stability

Applications:

• Investigating synergistic growth hormone release mechanisms

• Studying GHRH and ghrelin receptor interactions

• Preclinical research into endocrine regulation and peptide-mediated hormonal signaling

Safety and Handling:
For laboratory research use only. Not intended for human consumption or clinical application. Handle according to standard laboratory safety procedures and store under recommended conditions to preserve peptide integrity and stability.